Share

 
 

Want information on dosing?

Reimbursement & patient access?

See our Approved Products

References:

1.
Friedberg JW. Treatment of follicular non-Hodgkin's lymphoma: the old and the new. Semin Hematol. 2008;45(3 suppl 2):S2-S6.
2.
Hagemeister F, Cabanillas F, Coleman M, Gregory SA, Zinzani PL. The role of mitoxantrone in the treatment of indolent lymphomas. Oncologist. 2005;10:150-159.
3.
Friedberg JW, Taylor MD, Cerhan JR, et al. Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol. 2009;27:1202-1208.
4.
Sekeres MA, Kalaycio ME, Bolwell BJ, eds. Clinical Malignant Hematology. New York, NY: The McGraw-Hill Companies; 2007.
5.
Czuczman MS. Controversies in follicular lymphoma: "who, what, when, where, and why?" (not necessarily in that order!). Hematology Am Soc Hematol Educ Program. 2006:303-310.
6.
Hagenbeek A. Maintenance or eradication of residual disease in indolent lymphoma: where do we stand? J Clin Oncol. 2009;27:1540-1542.
7.
Staudt LM. A closer look at follicular lymphoma. N Engl J Med. 2007;356:741-742.
8.
Ansell SM, Armitage J. Non-Hodgkin lymphoma: diagnosis and treatment. Mayo Clin Proc. 2005;80:1087-1097.
9.
Dreyling M; ESMO Guidelines Working Group. Newly diagnosed and relapsed follicular lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20(suppl 4):119-120.
10.
The NCCN Non-Hodgkin's Lymphomas Clinical Practice Guidelines in Oncology (Version 1.2010). © 2010 National Comprehensive Cancer Network, Inc. http://www.nccn.org. Accessed June 7, 2010.
11.
Salles GA. Clinical features, prognosis and treatment of follicular lymphoma. Hematology Am Soc Hematol Educ Program. 2007:216-225.
12.
Skarin A. Diagnosis in oncology: primary low-grade lymphomas of the intestine. J Clin Oncol. 1999;17:3682-3683.
13.
Gribben JG. How I treat indolent lymphoma. Blood. 2007;109:4617-4626.
14.
Pazdur R, Coia LR, Hoskins WJ, Wagman LD, eds. Cancer Management: A Multidisciplinary Approach. 10th ed. Lawrence, KS: CMP Media LLC; 2007.
15.
Leich E, Salaverria I, Bea S, et al. Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations. Blood. 2009;114:826-834.
16.
Shiozawa E, Yamochi-Onizuka T, Yamochi T, et al. Disappearance of CD21-positive follicular dendritic cells preceding the transformation of follicular lymphoma: immunohistological study of the transformation using CD21, p53, Ki-67, and P-glycoprotein. Pathol Res Pract. 2003;199:293-302.
17.
Weiss LM, Loera S, Bacchi CE. Immunoglobulin light chain immunohistochemistry revisited, with emphasis on reactive follicular hyperplasia versus follicular lymphoma. Appl Immunohistochem Mol Morphol. 2010;18:199-205.
18.
Mantei K, Wood BL. Flow cytometric evaluation of CD38 expression assists in distinguishing follicular hyperplasia from follicular lymphoma. Cytometry B Clin Cytom. 2009;76:315-320.
19.
Greer JP, Williams ME. Non-Hodgkin Lymphoma in Adults. In: Greer JP, Foerster J, Rodgers GM, et al, eds. Wintrobe's Clinical Hematology. 12th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2009:2144-2194.
20.
Swerdlow SH, Campo E, Harris NL, et al. eds. WHO classification of tumors of hematopoietic and lymphoma tissues. 4th ed. Lyon, France: World Health Organization; 2008.
21.
Solal-Céligny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104:1258-1265.
22.
Montoto S, López-Guillermo A, Altés A, et al. A predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progression. Ann Oncol. 2004;15:1484-1489.
23.
Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009;27:4555-4562.
24.
Arcaini L, Merli M, Passamonti F, et al. Validation of follicular lymphoma international prognostic index 2 (FLIPI2) score in an independent series of follicular lymphoma patients. Br J Haematol. 2010;149:455-457.
25.
Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004;351:2159-2169.
26.
Carreras J, López-Guillermo A, Roncador G, et al. High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma. J Clin Oncol. 2009;27:1470-1476.
27.
Leonard JP. The "FLIPI" is no "FLOPI." Blood. 2004;104:1233-1234.
28.
Férme C, Vanel D, Ribrag V, Girinski T. Multidisciplinary symposium: hematological malignancies. Cancer Imaging. 2005;5:S113-S119.
29.
Solal-Céligny P, Lepage E, Brousse N, et al. Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 trial. J Clin Oncol. 1998;16:2332-2338.
30.
Friedberg JW. Potential long-term toxicities should influence the choice of therapy for indolent non-Hodgkin's lymphoma. Haematolgica. 2006;91:1453-1455.
31.
Seymour JF. Follicular lymphoma: maintenance therapy is (often) indicated. Nat Rev Clin Oncol. 2009:6:624-626.
32.
Horning SJ. Durable remissions in stage III follicular lymphoma: interpret with caution. J Clin Oncol. 1987;5:838-839.
33.
Horning SJ. Follicular lymphoma: have we made any progress? Ann Oncol. 2000;11(suppl 1):S23-S27.
34.
Advani R, Rosenberg SA, Horning SJ. Stage I and II follicular non-Hodgkin's lymphoma: long-term follow-up of no initial therapy. J Clin Oncol. 2004:22;1454-1459.
35.
US National Institutes of Health. ClinicalTrials.gov Web site. http://www.clinicaltrials.gov. Accessed June 8, 2010.
36.
Quintás-Cardama A, Wierda W, O'Brien S. Investigational immunotherapeutics for B-cell malignancies. J Clin Oncol. 2010;28:884-892.
37.
Briones J. Emerging therapies for B-cell non-Hodgkin lymphoma. Expert Rev Anticancer Ther. 2009;9:1305-1316.
38.
Freedman AS. Biology and management of histologic transformation of indolent lymphoma. Hematology Am Soc Hematol Educ Program. 2005;314-320.
39.
Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Engl J Med. 2008;359:613-626.
40.
Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer. 2006;6:714-727.
41.
Ivanov A, Beers SA, Walshe CA, et al. Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. J Clin Invest. 2009;119:2143-2159.
42.
Mössner E, Brünker P, Moser S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood. 2010;115:4393-4402.
43.
Tedder TF. CD19: a promising B cell target for rheumatoid arthritis. Nat Rev Rheumatol. 2009;5:572-577.
44.
Horton HM, Bernett MJ, Pong E, et al. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res. 2008;68:8049-8057.
45.
Vose JM. Antibody-targeted therapy for low-grade lymphoma. Semin Hematol. 1999;36:15-20.
46.
Cardarelli PM, Rao-Naik C, Chen S, et al. A nonfucosylated human antibody to CD19 with potent B-cell depletive activity for therapy of B-cell malignancies. Cancer Immunol Immunother. 2010;59:257-265.
47.
Hotta T. Anti-CD20 monoclonal antibody as a new treatment modality for B-cell lymphoma. Acta Histochem Cytochem. 2002;35:275-279.
48.
Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun. 2005;8:140-174.
49.
Rossi EA, Goldenberg DM, Cardillo TM, Stein R, Wang Y, Chang CH. Novel designs of multivalent anti-CD20 humanized antibodies as improved lymphoma therapeutics. Cancer Res. 2008;68:8384-8392.
50.
Vallera DA, Chen H, Sicheneder AR, Panoskaltsis-Mortari A, Taras EP. Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy. Leukemia Res. 2009;33:1233-1242.
51.
Polson AG, Calemine-Fenaux J, Chan P, et al. Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection. Cancer Res. 2009;69:2358-2364.
52.
Küppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer. 2005;5:251-262.
53.
Abramson JS, Shipp MA. Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. Blood. 2005;106:1164-1174.
54.
Richardson A, Kaye SB. Pharmacological inhibition of the bcl-2 family of apoptosis regulators as cancer therapy. Curr Mol Pharmacol. 2008;1:244-254.
55.
Pan LN, Lu J, Huang B. HDAC inhibitors: a potential new category of anti-tumor agents. Cell Mol Immunol. 2007;4:337-343.
56.
Dancey J. mTOR signaling and drug development in cancer. Nat Rev Clin Oncol. 2010;7:209-219.
57.
Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009;9:550-562.
58.
Leseux L, Hamdi SM, al Saati T, et al. Syk-dependent mTOR activation in follicular lymphoma cells. Blood. 2006;108:4156-4162.
59.
Baudot AD, Jeandel PY, Mouska X, et al. The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCδ and proteasome-dependent regulation of Mcl-1 expression. Oncogene. 2009;28:3261-3273.
60.
Kim SW, Rai D, McKeller MR, Aguiar RCT. Rational combined targeting of phosphodiesterase 4B and SYK in DLBCL. Blood. 2009;113:6153-6160.
61.
Chen L, Monti S, Juszczynski P, et al. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood. 2008;111:2230-2237.